{"id":62486,"date":"2026-01-13T19:06:16","date_gmt":"2026-01-13T18:06:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/"},"modified":"2026-01-13T19:06:16","modified_gmt":"2026-01-13T18:06:16","slug":"animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/","title":{"rendered":"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models"},"content":{"rendered":"
\n

\nTwo peptide programs validate the AnimateIQ\u2122 platform with strong anti-fibrotic efficacy, improved systemic health and broad biological relevance<\/i><\/p>\n

SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences<\/a> today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung fibrosis and inflammation. Notably, the company\u2019s lead peptide performed comparably to nintedanib, the current standard-of-care therapy.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe study evaluated two peptides derived from different genes and operating through distinct biological mechanisms. Both candidates demonstrated consistent efficacy across key disease endpoints, reinforcing the ability of Animate\u2019s AnimateIQ\u2122 discovery platform to generate multiple, independent therapeutic solutions within the same indication.<\/p>\n

\n\u201cDemonstrating that two distinct peptides deliver strong anti-inflammatory and anti-fibrotic effects validates both our platform and our pipeline strategy,\u201d said Peter Licari, CEO and co-founder of Animate. \u201cThis data strengthens our conviction that peptides discovered using the AnimateIQ\u2122 platform can deliver differentiated, disease-modifying therapies with the potential to improve lives.\u201d<\/p>\n

\nIn the bleomycin-induced lung fibrosis model, animals treated with Animate\u2019s peptides demonstrated improved systemic health, measured by body-weight recovery. Both peptides outperformed nintedanib, with treated animals exhibiting up to 34% greater weight gain versus the approved therapy, a meaningful indicator of improved tolerability and whole-body benefit in this disease model. Notably, neither peptide caused body-weight loss after 21 days of treatment.<\/p>\n

\nIn addition, both peptides significantly reduced lung fibrosis relative to diseased controls. The lead peptide matched nintedanib across established fibrosis measures, including hydroxyproline content and blinded Ashcroft scoring, and achieved greater than 85% reduction in disease-associated lung collagen deposition. The second peptide also demonstrated meaningful anti-fibrotic activity, further supporting platform robustness.<\/p>\n

\nAnimate\u2019s peptides also produced strong anti-inflammatory effects, with greater than 70% reductions in pro-inflammatory lung cell populations compared to positive controls.<\/p>\n

\nAcross all endpoints, both peptides exhibited clear dose-response relationships, supporting confidence in their pharmacologic activity and translational potential. These benefits were achieved at approximately 30% of the maximum tolerated dose, indicating a wide therapeutic window and significant headroom for clinical optimization.<\/p>\n

\n\u201cThese results show meaningful anti-fibrotic activity alongside improvement in systemic health,\u201d said Dr. Lonny Yarmus, Professor of Medicine and Oncology at The Johns Hopkins University School of Medicine, specializing in interventional pulmonology. \u201cSeeing consistent effects across established fibrosis measures at low doses supports the potential of this therapeutic approach.\u201d<\/p>\n

\nAnimate\u2019s peptides have demonstrated activity across multiple human cell types in vitro<\/i>, including lung, dermal, cardiac and liver cells, supporting a multi-organ strategy. Animate Biosciences is advancing a pipeline of AI-designed peptides targeting inflammation and fibrosis across the lung, heart, liver and skin and is progressing toward IND-enabling studies. For more information, visit animate.bio<\/a>.<\/p>\n

\nAbout Animate Biosciences<\/span><\/b><\/p>\n

\nAnimate Biosciences is a biotechnology company developing first-of-its-kind peptide therapeutics to stop inflammatory and fibrotic disease. Powered by its proprietary AnimateIQ\u2122 platform, the company combines breakthroughs in biological data processing, generative AI and rapid peptide synthesis to design novel therapies. By leveraging the untapped biology of nature\u2019s best regenerators, the company aims to transform how inflammation and fibrosis are treated across organ systems, make advanced therapeutics accessible and deliver a future where life-altering or life-ending inflammatory and fibrotic disease is no longer inevitable. For more information, visit animate.bio<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
Carly Kuikman
\n
carly@cskpublicrelations.com<\/a>
(978) 604 – 0904<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Two peptide programs validate the AnimateIQ\u2122 platform with strong anti-fibrotic efficacy, improved systemic health and broad biological relevance SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung fibrosis and inflammation. Notably, the company\u2019s lead peptide performed comparably … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62486","6":"format-standard","7":"category-industry"},"yoast_head":"\nAnimate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Two peptide programs validate the AnimateIQ\u2122 platform with strong anti-fibrotic efficacy, improved systemic health and broad biological relevance SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung fibrosis and inflammation. Notably, the company\u2019s lead peptide performed comparably ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T18:06:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260113209826\/en\/2686551\/22\/Animate_Bio_Logo_%283%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models\",\"datePublished\":\"2026-01-13T18:06:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/\"},\"wordCount\":549,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260113209826\\\/en\\\/2686551\\\/22\\\/Animate_Bio_Logo_%283%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/\",\"name\":\"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260113209826\\\/en\\\/2686551\\\/22\\\/Animate_Bio_Logo_%283%29.jpg\",\"datePublished\":\"2026-01-13T18:06:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260113209826\\\/en\\\/2686551\\\/22\\\/Animate_Bio_Logo_%283%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260113209826\\\/en\\\/2686551\\\/22\\\/Animate_Bio_Logo_%283%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/","og_locale":"en_US","og_type":"article","og_title":"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models - Pharma Trend","og_description":"Two peptide programs validate the AnimateIQ\u2122 platform with strong anti-fibrotic efficacy, improved systemic health and broad biological relevance SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung fibrosis and inflammation. Notably, the company\u2019s lead peptide performed comparably ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-13T18:06:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260113209826\/en\/2686551\/22\/Animate_Bio_Logo_%283%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models","datePublished":"2026-01-13T18:06:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/"},"wordCount":549,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260113209826\/en\/2686551\/22\/Animate_Bio_Logo_%283%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/","url":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/","name":"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260113209826\/en\/2686551\/22\/Animate_Bio_Logo_%283%29.jpg","datePublished":"2026-01-13T18:06:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260113209826\/en\/2686551\/22\/Animate_Bio_Logo_%283%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260113209826\/en\/2686551\/22\/Animate_Bio_Logo_%283%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-engineered-peptides-match-or-exceed-standard-therapy-in-preclinical-lung-fibrosis-models\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Animate Biosciences\u2019 Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62486"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62486\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}